EUCTR2009-017004-91-FR进行中（未招募）1 期
A randomised, double-blind, placebo-controlled parallel group dose finding study of linagliptin (1 mg or 5 mg administered orally once daily) over 12 weeks in children and adolescents, from 10 to 17 years of age, with type 2 diabetes and insufficient glycaemic control despite treatment with diet and exercise alone
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 83
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Paediatric patients, aged 10 to 17 years at the time of screening (i.e. Visit 1A)
- •Documented diagnosis of type 2 diabetes mellitus at least 3 months prior to randomisation (i.e. Visit 2)
- •Insufficient glycaemic control (i.e. an HbA1c > 7.0% and = 10.0%) at screening despite treatment with diet and exercise alone
- •Negative for islet cell antigen (ICA) auto-antibodies and glutamic acid decarboxylase (GAD) auto-antibodies at Visit 2
- •C-peptide levels (serum) = 1.5 ng/ml (at 90 min following a Boost challenge) at Visit 2
- •Compliance during the open-label placebo run-in period between 75% and 125%.
- •Written informed consent provided by the patient’s parent(s) (or legal guardian) and assent by the patient at the latest by the date of Visit 1A in accordance with GCP and local legislation. Informed assent will be sought according to the patient’s age, level of maturity, competence and capacity. All informed consent/assent forms will be consistent with ICH-GCP and local IEC/IRB requirements.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Uncontrolled hyperglycaemia with a glucose level > 240 mg/dl (> 13.3 mmol/l) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day)
- •History of acute metabolic decompensation, such as diabetic ketoacidosis, within 3 months of screening
- •Current insulin therapy, or having received insulin for > 4 weeks within the 3 months prior to randomisation
- •Treatment with weight reduction medications (including anti-obesity treatments) within 3 months prior to randomisation
- •Chronic treatment – treatment duration of more than two weeks - with medication known to affect glucose metabolism within 3 months prior to randomisation
- •Anticipated need for treatment with PGP (P-glycoprotein) and CYP 3A4 inhibitors or inducers during the study.
- •Clinically significant renal disease (defined as estimated Glomerular Filtration Rate [eGFR] < 60 ml/min, i.e. moderate and severe renal impairment, calculated according to the Schwarz formula) as determined at screening
- •Clinically significant hepatic disease (defined as persistent serum levels of ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at screening
- •Gastrointestinal disorders that might interfere with study drug absorption
- •Patients presenting a secondary obesity as part of a syndrome (e.g. : Prader-Willi syndrome)
- •Female patients who are nursing or are pregnant
- •Female patients who have reached menarche (i.e. ANY vaginal bleeding, however scant or irregular) with a positive pregnancy test or who are sexually active and not using a medically accepted contraceptive method. Acceptable methods of birth control are limited to: intra-uterine device (IUD); oral, implantable or injectable contraceptives and oestrogen patch; double-barrier method (spermicide plus diaphragm); or abstinence (if permitted by local authorities) at the discretion of the Investigator
- •Patients with a history of belonephobia (needle phobia) in this age group
- •Patients with anaemia defined as shown below and as determined at screening:
- •children aged up to 12: haemoglobin of < 11.5 g/dl and haematocrit < 35%
- •females aged > 12 or who reached menarche before this age: haemoglobin of < 12 g/dl and haematocrit < 36%
- •males aged > 12: haemoglobin of < 13 g/dl and haematocrit < 39%
- •Active alcohol or drug abuse within the 3 months prior to informed consent
- •Patients whose parent(s) (or legal guardian) will be unable to support the reporting of adverse event information
- •Patients whose home circumstances will mean they are unable to store the study rescue medication (insulin) appropriately
- •Known hypersensitivity or allergy to the investigational product or its excipients or placebo
- •Participation in another trial with an investigational drug within 2 months prior to informed consent
- •Patients considered unreliable by the Investigator concerning the requirements for follow-up during the study and/or compliance with study medication administration
- •Any disease or clinically significant abnormality/clinical condition that may increase the risk associated with study participation or affect the study outcome, and in the judgement of the Investigator would make the patient inappropriate for entry into the study
研究者
相似试验
进行中（未招募）
1 期
A study to test how taking BI 1015550 for 12 weeks affects lungfunction in people with idiopathic pulmonary fibrosis (IPF).MedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersIdiopathic Pulmonary FibrosisEUCTR2019-004167-45-FIBoehringer Ingelheim Finland Ky150
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite a therapy of metformin in combination with a sulphonylureaEUCTR2007-002450-28-BESCS Boehringer Ingelheim Comm.V800
进行中（未招募）
不适用
Tiotropium-bromide in cystic fibrosicMedDRA version: 14.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2010-019802-17-CZBoehringer Ingelheim360
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks, in drug naive or previously treated (6 weeks washout) type 2 diabetic patients with insufficient glycaemic controlEUCTR2007-002448-10-SK450
进行中（未招募）
1 期
Effic. PK + safety in paed. patientsPatients with type 2 diabetes.MedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2009-017004-91-ITBOEHRINGER ING.255